Taros Chemicals Appoints Torsten Hoffmann as Senior Vice President Drug Discovery

Taros Chemicals GmbH & Co. KG today announced the appointment of Dr Torsten Hoffmann as Senior Vice President Drug Discovery, effective October 1st, 2018. In his role, Torsten will further strengthen and accelerate Taros’ continued growth of its drug discovery business.

With more than 20 years of international R&D leadership experience, Torsten is an expert in the field of Drug Discovery. For the past 5 years he has served as Chief Operating Officer and Chief Scientific Officer at Silence Therapeutics Plc, as Chief Scientific Officer and Managing Director at Proteros biostructures GmbH, and prior to that as Chief Scientific Officer and Executive Vice President at Zealand Pharma A/S. During this tenure and under his leadership, he has been instrumental in building and growing the proprietary R&D portfolios of these biotech companies with the most advanced assets now being developed in clinical phase 3 trials.

Torsten started his career at Roche where he spent 16 years in various roles with increasing responsibility including Site Head of Medicinal Chemistry in Basel, and Head of the Global Roche Postdoc Fellowship Program. Under his leadership, his group created 52 new chemical lead series and more than 25 NCEs entered clinical trials as potential Roche medicines. Moreover, he is the lead inventor of the anti-emetic medicine Netupitant, discovered at Roche and approved by the FDA as Akynzeo© in 2014.

Commenting on the appointment, Dr Dimitrios Tzalis, Founder & CEO said:
“We are very delighted that Torsten has joined Taros at this pivotal time for the company. As we continue to develop our drug discovery chemistry business, Torsten will add extensive industrial sector experience as well as an outstanding track record in medicinal chemistry and drug discovery collaborations. I am confident this will not only boost our own efforts, indeed the whole Drug Discovery Hub in Dortmund will benefit from his experience. I am very much looking forward to collaborating with Torsten as he will participate in shaping the future of Taros regarding integrated drug discovery chemistry and proprietary technologies.”

Dr Torsten Hoffmann added:
"These are exciting times for Taros currently providing expertise and tangible results to its partners through drug discovery campaigns in various therapeutic areas. In addition, building on the enormous potential, created during the EUR 196 million funded European Lead Factory (ELF), will be an excellent opportunity to further accelerate Taros’ expansion into Drug Discovery. It will be my great pleasure working with this enthusiastic team in Dortmund as well as connecting to the inspiring network of highly talented scientists within the entire Drug Discovery cluster."

About Taros Chemicals

Taros, a privately owned CRO have been serving the needs of pharmaceutical, biotech and chemical companies since 1999. Within our drug discovery chemistry services, our mission is to accelerate potential new medicines into clinical development. Taros’ scientists add considerable value to drug discovery collaborations by providing advanced scientific knowledge and intellectual input to a boost clients’ discovery programs from target validation, through hit identification, hit-to-lead and lead optimization. Taros’ capabilities include medicinal chemistry, computational sciences & informatics, bioscience and DMPK/physical sciences via its network. Taros Chemicals has been leading the chemistry activities of the European Lead Factory (ELF), EU’s 196 million early drug discovery platform and are now partnering in the new German Drug Discovery Hub Dortmund (DDHD) initiative.

For further information, please contact:

Taros Chemicals GmbH Co. KG
Emil-Figge-Str. 76a
44227 Dortmund
Dr Dimitrios Tzalis
Tel.: +49 (0)231 974272-11, e-mail: info@taros.de

This release was published on openPR.